Introducing Lonrú Consulting
Navigating Complexity
Illuminating Innovation
Empowering the Future of Cell and Gene Therapy
The cell and gene therapy (CGT) sector is experiencing unprecedented growth, diversification, and challenges (McKinsey & Co., 2022). At Lonrú Consulting, we’re here to help organisations navigate this complex landscape by providing tailored solutions that empower innovation, optimise efficiency, and drive impactful results.
Our Mission
Lonrú Consulting is dedicated to delivering data-driven insights and actionable strategies that address the unique challenges of the CGT industry. Through collaboration, advanced tools, and domain expertise, we guide clients toward sustainable growth and innovation in a highly competitive market.
Why Now for AI/ML?
The rapid evolution of AI/ML tools over the last 18 months has transformed how organisations address critical challenges across many industries. The wider adoption of AI/ML in the life sciences field has triggered both excitement and caution (Nature, 2023). On one hand, these tools promise to revolutionise processes such as drug discovery, regulatory navigation, and patient engagement (Hutson 2024). On the other hand, perceptions of these tools as “black boxes” with potential accuracy and reliability issues have made some organisations hesitant to fully commit (McKinsey & Co., 2023). Despite these concerns, the tide is shifting as the technology continues to improve and demonstrate measurable impact.
Perceptions in Life Sciences
Early adopters of AI/ML in life sciences report a 30% improvement in engagement and satisfaction scores when using AI/ML powered tools for content personalisation and insight generation. Many life sciences leaders emphasise the importance of clear AI strategies, with companies adopting customised solutions seeing twice the impact compared to those using off-the-shelf models (McKinsey & Co., 2023). However, challenges such as data privacy, algorithmic transparency, and the potential for misinformation (e.g., hallucinations in outputs) continue to shape perceptions (Nature Editorial, 2024).
Building Confidence in AI for CGT
Transparency and customisation are critical to unlocking the full potential of AI in life sciences. Companies with defined AI strategies report twice the impact compared to those without (McKinsey & Co. 2023). At Lonrú, we ensure that every AI-powered solution is tailored to meet our clients’ specific goals, fostering trust and maximizing outcomes.
How Lonrú Can Help
Our AI/ML-driven solutions evolve with client needs, ensuring relevance in the fast-paced CGT landscape. By blending cutting-edge technology with domain expertise, we address industry-specific challenges and enable our clients to:
Analyze Data Effectively: Transform complex datasets into actionable insights.
Optimize Workflows: Eliminate inefficiencies and boost productivity.
Facilitate Collaboration: Connect biotechs, academia, and investors to foster innovation and growth.
In an industry where speed, precision, and trust are paramount, Lonrú equips clients to navigate complexity confidently, seize emerging opportunities, and drive impactful innovation.
Stay updated on our capabilities and projects by connecting with Lonrú Consulting on LinkedIn using the link below.
References
Hutson, M. (2024, March 14th). Cutting to the chase. Health sciences. https://media.nature.com/original/magazine-assets/d41586-024-00753-x/d41586-024-00753-x.pdf
McKinsey & Co. (2022, November 16th). How AI can accelerate R&D for cell and gene therapies. Life Sciences. https://www.mckinsey.com/industries/life-sciences/our-insights/how-ai-can-accelerate-r-and-d-for-cell-and-gene-therapies
McKinsey & Co. (2023, May 6th). Early adoption of generative AI in commercial life sciences. McKinsey Direct. https://www.mckinsey.com/industries/life-sciences/our-insights/early-adoption-of-generative-AI-in-commercial-life-sciences#/
Nature. (2023, December 6). Science and the new age of AI. Immersive. https://www.nature.com/immersive/d41586-023-03017-2
